Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy

Kazuhiko Kurozumi, Jayson Hardcastle, Roopa Thakur, Ming Yang, Gregory Christoforidis, Giulia Fulci, Fred H. Hochberg, Ralph Weissleder, William Carson, E. Antonio Chiocca, Balveen Kaur

Research output: Contribution to journalArticle

120 Citations (Scopus)

Abstract

Background. The tumor microenvironment is being increasingly recognized as an important determinant of tumor progression as well as of therapeutic response. We investigated oncolytic virus (OV) therapy-induced changes in tumor blood vessels and the impact of modulating tumor vasculature on the efficacy of oncolytic virus therapy. Methods. Rat glioma cells (D74/HveC) were implanted intracranially in immune-competent rats. Seven days later, the rats (groups of 3-7 rats) were treated with oncolytic virus (hrR3), and, 3 days later, brains were harvested for evaluation. Some rats were treated with angiostatic cRGD peptide 4 days before oncolytic virus treatment. Some rats were treated with cyclophosphamide (CPA), an immunosuppressant, 2 days before oncolytic virus treatment. Changes in tumor vascular perfusion were evaluated by magnetic resonance imaging of live rats and by fluorescence microscopy of tumor sections from rats perfused with Texas red-conjugated lectin immediately before euthanasia. Leukocyte infiltration in tumors was evaluated by anti-CD45 immunohistochemistry, and the presence of oncolytic virus in tumors was evaluated by viral titration. Changes in cytokine gene expression in tumors were measured by quantitative real-time polymerase chain reaction-based microarrays. Survival was analyzed by the Kaplan-Meier method. All statistical tests were two-sided. Results. Oncolytic virus treatment of experimental rat gliomas increased tumor vascular permeability, host leukocyte infiltration into tumors, and intratumoral expression of inflammatory cytokine genes, including interferon gamma (IFN-γ). The increase in vascular permeability was suppressed in rats pretreated with cyclophosphamide. Compared with rats treated with hrR3 alone, rats pretreated with a single dose of cRGD peptide before hrR3 treatment had reduced tumor vascular permeability, leukocyte infiltration, and IFN-γ protein levels (mean IFN-γ level for hrR3 versus hrR3 + cRGD = 203 versus 65.6 μg/mg, difference = 137 μg/mg, 95% confidence interval = 72.7 to 202.9 μg/mg, P =. 006); increased viral titers in tumor tissue; and longer median survival (21 days versus 17 days, P

Original languageEnglish
Pages (from-to)1768-1781
Number of pages14
JournalJournal of the National Cancer Institute
Volume99
Issue number23
DOIs
Publication statusPublished - Dec 2007
Externally publishedYes

Fingerprint

Oncolytic Virotherapy
Tumor Microenvironment
Oncolytic Viruses
Neoplasms
Capillary Permeability
Interferon-gamma
Angiostatic Proteins
Glioma
Cyclophosphamide
Leukocytes
Vascular Tissue Neoplasms
Cytokines
Therapeutics
Euthanasia
Immunosuppressive Agents
Fluorescence Microscopy
Lectins
Interferon-alpha

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. / Kurozumi, Kazuhiko; Hardcastle, Jayson; Thakur, Roopa; Yang, Ming; Christoforidis, Gregory; Fulci, Giulia; Hochberg, Fred H.; Weissleder, Ralph; Carson, William; Chiocca, E. Antonio; Kaur, Balveen.

In: Journal of the National Cancer Institute, Vol. 99, No. 23, 12.2007, p. 1768-1781.

Research output: Contribution to journalArticle

Kurozumi, K, Hardcastle, J, Thakur, R, Yang, M, Christoforidis, G, Fulci, G, Hochberg, FH, Weissleder, R, Carson, W, Chiocca, EA & Kaur, B 2007, 'Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy', Journal of the National Cancer Institute, vol. 99, no. 23, pp. 1768-1781. https://doi.org/10.1093/jnci/djm229
Kurozumi, Kazuhiko ; Hardcastle, Jayson ; Thakur, Roopa ; Yang, Ming ; Christoforidis, Gregory ; Fulci, Giulia ; Hochberg, Fred H. ; Weissleder, Ralph ; Carson, William ; Chiocca, E. Antonio ; Kaur, Balveen. / Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. In: Journal of the National Cancer Institute. 2007 ; Vol. 99, No. 23. pp. 1768-1781.
@article{2df662b5a2314891b6796ecd9552a91a,
title = "Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy",
abstract = "Background. The tumor microenvironment is being increasingly recognized as an important determinant of tumor progression as well as of therapeutic response. We investigated oncolytic virus (OV) therapy-induced changes in tumor blood vessels and the impact of modulating tumor vasculature on the efficacy of oncolytic virus therapy. Methods. Rat glioma cells (D74/HveC) were implanted intracranially in immune-competent rats. Seven days later, the rats (groups of 3-7 rats) were treated with oncolytic virus (hrR3), and, 3 days later, brains were harvested for evaluation. Some rats were treated with angiostatic cRGD peptide 4 days before oncolytic virus treatment. Some rats were treated with cyclophosphamide (CPA), an immunosuppressant, 2 days before oncolytic virus treatment. Changes in tumor vascular perfusion were evaluated by magnetic resonance imaging of live rats and by fluorescence microscopy of tumor sections from rats perfused with Texas red-conjugated lectin immediately before euthanasia. Leukocyte infiltration in tumors was evaluated by anti-CD45 immunohistochemistry, and the presence of oncolytic virus in tumors was evaluated by viral titration. Changes in cytokine gene expression in tumors were measured by quantitative real-time polymerase chain reaction-based microarrays. Survival was analyzed by the Kaplan-Meier method. All statistical tests were two-sided. Results. Oncolytic virus treatment of experimental rat gliomas increased tumor vascular permeability, host leukocyte infiltration into tumors, and intratumoral expression of inflammatory cytokine genes, including interferon gamma (IFN-γ). The increase in vascular permeability was suppressed in rats pretreated with cyclophosphamide. Compared with rats treated with hrR3 alone, rats pretreated with a single dose of cRGD peptide before hrR3 treatment had reduced tumor vascular permeability, leukocyte infiltration, and IFN-γ protein levels (mean IFN-γ level for hrR3 versus hrR3 + cRGD = 203 versus 65.6 μg/mg, difference = 137 μg/mg, 95{\%} confidence interval = 72.7 to 202.9 μg/mg, P =. 006); increased viral titers in tumor tissue; and longer median survival (21 days versus 17 days, P",
author = "Kazuhiko Kurozumi and Jayson Hardcastle and Roopa Thakur and Ming Yang and Gregory Christoforidis and Giulia Fulci and Hochberg, {Fred H.} and Ralph Weissleder and William Carson and Chiocca, {E. Antonio} and Balveen Kaur",
year = "2007",
month = "12",
doi = "10.1093/jnci/djm229",
language = "English",
volume = "99",
pages = "1768--1781",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "23",

}

TY - JOUR

T1 - Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy

AU - Kurozumi, Kazuhiko

AU - Hardcastle, Jayson

AU - Thakur, Roopa

AU - Yang, Ming

AU - Christoforidis, Gregory

AU - Fulci, Giulia

AU - Hochberg, Fred H.

AU - Weissleder, Ralph

AU - Carson, William

AU - Chiocca, E. Antonio

AU - Kaur, Balveen

PY - 2007/12

Y1 - 2007/12

N2 - Background. The tumor microenvironment is being increasingly recognized as an important determinant of tumor progression as well as of therapeutic response. We investigated oncolytic virus (OV) therapy-induced changes in tumor blood vessels and the impact of modulating tumor vasculature on the efficacy of oncolytic virus therapy. Methods. Rat glioma cells (D74/HveC) were implanted intracranially in immune-competent rats. Seven days later, the rats (groups of 3-7 rats) were treated with oncolytic virus (hrR3), and, 3 days later, brains were harvested for evaluation. Some rats were treated with angiostatic cRGD peptide 4 days before oncolytic virus treatment. Some rats were treated with cyclophosphamide (CPA), an immunosuppressant, 2 days before oncolytic virus treatment. Changes in tumor vascular perfusion were evaluated by magnetic resonance imaging of live rats and by fluorescence microscopy of tumor sections from rats perfused with Texas red-conjugated lectin immediately before euthanasia. Leukocyte infiltration in tumors was evaluated by anti-CD45 immunohistochemistry, and the presence of oncolytic virus in tumors was evaluated by viral titration. Changes in cytokine gene expression in tumors were measured by quantitative real-time polymerase chain reaction-based microarrays. Survival was analyzed by the Kaplan-Meier method. All statistical tests were two-sided. Results. Oncolytic virus treatment of experimental rat gliomas increased tumor vascular permeability, host leukocyte infiltration into tumors, and intratumoral expression of inflammatory cytokine genes, including interferon gamma (IFN-γ). The increase in vascular permeability was suppressed in rats pretreated with cyclophosphamide. Compared with rats treated with hrR3 alone, rats pretreated with a single dose of cRGD peptide before hrR3 treatment had reduced tumor vascular permeability, leukocyte infiltration, and IFN-γ protein levels (mean IFN-γ level for hrR3 versus hrR3 + cRGD = 203 versus 65.6 μg/mg, difference = 137 μg/mg, 95% confidence interval = 72.7 to 202.9 μg/mg, P =. 006); increased viral titers in tumor tissue; and longer median survival (21 days versus 17 days, P

AB - Background. The tumor microenvironment is being increasingly recognized as an important determinant of tumor progression as well as of therapeutic response. We investigated oncolytic virus (OV) therapy-induced changes in tumor blood vessels and the impact of modulating tumor vasculature on the efficacy of oncolytic virus therapy. Methods. Rat glioma cells (D74/HveC) were implanted intracranially in immune-competent rats. Seven days later, the rats (groups of 3-7 rats) were treated with oncolytic virus (hrR3), and, 3 days later, brains were harvested for evaluation. Some rats were treated with angiostatic cRGD peptide 4 days before oncolytic virus treatment. Some rats were treated with cyclophosphamide (CPA), an immunosuppressant, 2 days before oncolytic virus treatment. Changes in tumor vascular perfusion were evaluated by magnetic resonance imaging of live rats and by fluorescence microscopy of tumor sections from rats perfused with Texas red-conjugated lectin immediately before euthanasia. Leukocyte infiltration in tumors was evaluated by anti-CD45 immunohistochemistry, and the presence of oncolytic virus in tumors was evaluated by viral titration. Changes in cytokine gene expression in tumors were measured by quantitative real-time polymerase chain reaction-based microarrays. Survival was analyzed by the Kaplan-Meier method. All statistical tests were two-sided. Results. Oncolytic virus treatment of experimental rat gliomas increased tumor vascular permeability, host leukocyte infiltration into tumors, and intratumoral expression of inflammatory cytokine genes, including interferon gamma (IFN-γ). The increase in vascular permeability was suppressed in rats pretreated with cyclophosphamide. Compared with rats treated with hrR3 alone, rats pretreated with a single dose of cRGD peptide before hrR3 treatment had reduced tumor vascular permeability, leukocyte infiltration, and IFN-γ protein levels (mean IFN-γ level for hrR3 versus hrR3 + cRGD = 203 versus 65.6 μg/mg, difference = 137 μg/mg, 95% confidence interval = 72.7 to 202.9 μg/mg, P =. 006); increased viral titers in tumor tissue; and longer median survival (21 days versus 17 days, P

UR - http://www.scopus.com/inward/record.url?scp=38449114010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38449114010&partnerID=8YFLogxK

U2 - 10.1093/jnci/djm229

DO - 10.1093/jnci/djm229

M3 - Article

C2 - 18042934

AN - SCOPUS:38449114010

VL - 99

SP - 1768

EP - 1781

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 23

ER -